OCREVUS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Nigeria, Poland, Romania, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug OCREVUS contains one active pharmaceutical ingredient (API):

1	Ocrelizumab UNII A10SJL62JY - OCRELIZUMAB
	Ocrelizumab is a recombinant humanised monoclonal antibody that selectively targets CD20-expressing B cells. The precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects in MS is presumed to involve immunomodulation through the reduction in the number and function of CD20-expressing B cells. Following cell surface binding, ocrelizumab selectively depletes CD20-expressing B cells through antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. The capacity of B-cell reconstitution and preexisting humoral immunity are preserved.
	Read more about Ocrelizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OCREVUS Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG08		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11237K, 11242Q
BR	Câmara de Regulação do Mercado de Medicamentos	529218060027101
CA	Health Products and Food Branch	02467224
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	126-MBE-0418
EE	Ravimiamet	1762422, 1762433
ES	Centro de información online de medicamentos de la AEMPS	1171231001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	405139
FR	Base de données publique des médicaments	66127361
GB	Medicines & Healthcare Products Regulatory Agency	350585, 354242
IL	מִשְׂרַד הַבְּרִיאוּת	8347
IT	Agenzia del Farmaco	045889019, 045889021
LT	Valstybinė vaistų kontrolės tarnyba	1084789, 1084790
NG	Registered Drug Product Database	A6-100051
Switch country to Nigeria in order to find specific presentations of OCREVUS
NL	Z-Index G-Standaard, PRK	149322
NZ	Medicines and Medical Devices Safety Authority	18432
PL	Rejestru Produktów Leczniczych	100399341
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64485001
TN	Direction de la Pharmacie et du Médicament	6993221H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699505761954, 8699505761978
US	FDA, National Drug Code	50242-150